COMP <GO>
AXON vs TMO // FORWARD P/E MULTIPLE
Axon Enterprise Inc. (NASDAQ) VS. Thermo Fisher Scientific Inc (NYSE) • 15-METRIC TALLY: AXON 4
— TMO 9
▲ FORWARD P/E MULTIPLE LEADER: TMO
LAST: $427.77 (-2.35%) • MKT CAP: $35.59B
forward-pe
140.0x
LAST: $697.00 (-1.72%) • MKT CAP: $262.22B
forward-pe
36.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AXON VS. TMO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | AXON | TMO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 59.70% | 41.00% | +18.70 | AXON | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -1.30% | 9.30% | -10.60 | TMO | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 30.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 0.21% | 2.40% | -2.19 | TMO | /fcf-yield <GO> |
| Operating Margin | -2.20% | 17.40% | -19.60 | TMO | /operating-margins <GO> |
| Net Profit Margin | 4.50% | 15.10% | -10.60 | TMO | /net-margins <GO> |
| Revenue Growth (YoY) | 33.50% | 3.90% | +29.60 | AXON | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.24% | -0.24 | TMO | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 6.62 | 4.50 | +2.12 | AXON | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.10% | 6.70% | +0.40 | TMO | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 49.4 | 59.1 | -9.72 | TMO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.06 | 0.94 | +0.12 | AXON | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 140.0x | 36.3x | +103.70 | TMO | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $35.59B | $262.22B | -$226.63B | TMO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | AXON REV | TMO REV | AXON GROSS % | TMO GROSS % | AXON FCF | TMO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.78B | $44.56B | 59.7% | 44.0% | $75.1M | $6.29B |
| FY 2024 | $2.08B | $42.88B | 59.6% | 44.0% | $329.5M | $7.27B |
| FY 2023 | $1.56B | $42.86B | 44.0% | 44.0% | $119.0M | $6.48B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AXON // BETA 1.06
TMO // BETA 0.94